The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Incidence of COVID-19 infections in vaccinated patients with CLL
Chaitra Ujjani, MD, University of Washington & Fred Hutchinson Cancer Research Center, Seattle, WA, discusses the findings of a prospective observational study (NCT04852822) evaluating the efficacy of the SARS-CoV-2 vaccine in patients with chronic lymphocytic leukemia (CLL). The vaccine induced lower response rates in CLL patients when compared to healthy individuals. Furthermore, infection rates in patients were substantially higher following the booster dose, likely due to less stringent social distancing and masking practices and the emergence of new viral strains. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Lilly, Janssen, Pharmacyclics, Genentech, Beigene, Kite, a Gilead Company, Epizyme, Astrazeneca, Abbvie, Atara; Honoraria: Lilly, Janssen, Pharmacyclics, Genentech, Beigene, Astrazeneca, Abbvie; Research Funding: Lilly, Pharmacyclics, PCYC, Kite, a Gilead Company, Astrazeneca, Abbvie; Travel expenses: Kite, a Gilead Company
